middle.news
Can Chimeric’s CORE-NK Cells Transform Frontline AML Treatment?
2:26am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Can Chimeric’s CORE-NK Cells Transform Frontline AML Treatment?
2:26am on Monday 2nd of June, 2025 AEST
Key Points
Two of three evaluable patients achieved Complete Response with incomplete blood count recovery (CRi)
ADVENT-AML is the first frontline AML trial incorporating cell therapy
Trial targets elderly or unfit AML patients ineligible for chemotherapy or transplant
No safety concerns observed in dose-finding phase
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE